117 results about "Immunotherapeutic agent" patented technology

A chitosan-heparin nanomotor and a method for producing same are disclosed. A STING agonist-encapsulated urease-based chitosan-heparin nanomotor delivers the STING agonist directly to bladder mucosal cells in the bladder, and thus can induce an immune response.

Disclosed herein are methods of using OX40 as a biomarker for predicting clinical sensitivity and therapeutic response of subjects having cancer to treatment with immunotherapeutic agents, and methods of using OX40 as a biomarker for selecting patient population for cancer treatment with immunotherapeutic agents. Disclosed herein are also methods of treating OX40-expressing cancers using immunotherapeutic agents. Further provided herein are kit for predicting the responsiveness of a subject having cancer to treatment with immunotherapeutic agents.

Methods and compositions using novel Cbl inhibitors enhancing expansion of immune cells to increase the efficacy of cell-based immunotherapeutics are disclosed. Also provided are cell-based immunotherapy methods and compositions.

The present invention relates to a chemo combination therapy regimen to treat cancer. More specifically, the present invention relates to a novel chemo combination therapy regimen which relates to the combination of compound AL3818 (anlotinib, catequentinib) or its pharmaceutically acceptable salts with standard platinum-based and other chemotherapy agents or immunotherapy agents. The combination of these agents should be able to provide higher efficacy than employing any agent individually.

Provided are methods and compositions for enhancing radiotherapy in various cancers by administering dopamine receptor (DRD2)‐binding phenylpiperazine derivatives such as brexpiprazole, cariprazine, pipamperone, and perospirone. In vitro studies show that combining these agents with ionizing radiation (e.g., 5 Gy) significantly reduces cancer cell survival, suppresses metastatic and stemness markers (e.g., CD44, MMP‑2, Snail, Nanog), and promotes apoptosis. Fractionated or single‐fraction radiation regimens can be paired with DRD2 antagonists to lower treatment‐resistant phenotypes, decrease the likelihood of recurrence, and potentially reduce necessary radiation dosages. The approach applies to breast, prostate, lung, pancreatic, and brain cancers, among others. Depending on tumor characteristics, additional chemotherapeutic or immunotherapeutic agents may further improve outcomes.

Devices, systems, and methods can be used for the automated production of dendritic cells (DC) from dendritic cell progenitors, such as monocytes obtained from peripheral blood, and the automated generation of immunotherapeutic products from those dendritic cells, all within a closed system. The invention makes it possible to obtain sufficient quantities of a subject's own DC for use in preparing and characterizing vaccines, for activating and characterizing the activation state of the subject's immune response, and to aid in preventing and / or treating cancer or infectious disease.

The present disclosure relates to biodegradable polymeric microspheres comprising a biodegradable polymer and an immunotherapeutic agent selected from the group consisting of a poly ADP ribose polymerase inhibitor (PARP inhibitor) and / or a Toll-like receptor (TLR) agonist, wherein (a) 50% of the total amount of the immunotherapeutic agent in the biodegradable polymer microspheres is released from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; (b) releasing the immunotherapeutic agent with the dry weight of 1 mg / g to 100 mg / g from the biodegradable polymer microspheres to a PBS solution containing 0.05% of Tween 20 at 37 DEG C at a certain time point between 3 days and 14 days; or (c) satisfies both (a) and (b). Other aspects of the present disclosure relate to methods of using such microparticles and kits comprising such microparticles.

To provide a new immunotherapeutic agent useful for treating obesity.SOLUTION: The pharmaceutical composition contains a peptide having a specific amino acid sequence containing a B cell epitope. Preferably the composition includes an aluminium salt (Alhydrogel (Al (OH) 3) and monophosphoryl lipid A as adjuvants. Intramuscular administration of the composition to a subject results in the production of antibodies capable of binding to ApoB-100 in vivo, and the antibodies exert a therapeutic effect on obesity.SELECTED DRAWING: Figure 14

The present invention relates to a method for selecting a patient group predicted to respond to immunotherapy cancer treatment. According to the method of the present invention, it is possible to distinguish, in advance, between a patient group that is likely to respond to anti-TIGIT and / or anti-IL-6 immunotherapeutic agents and a patient group that is unlikely to respond to same, enabling effective treatment to be performed, and thus the method is expected to be widely applicable in the medical field.

Provided herein are multiepitope peptides comprising at least one mucin 1 (MUC1) peptide, having MHC affinity for at least one HLA serotype, and recognized by CD4+ T cell receptors and / or CD8+ T cell receptors. Also provided herein are compositions comprising the multiepitope peptides and a cationic lipid, including vaccine compositions. In various embodiments, the cationic lipid is R-DOTAP. The present invention also provides methods of using the multiepitope peptides, as well as compositions and vaccine compositions. These methods of use include methods for treating cancer in a subject and methods for inducing MUC-specific polyfunctional and cytolytic T cell responses in a subject.

The invention belongs to the field of biological medicine, and relates to application of an SIRT2 inhibitor in preparation of a colorectal cancer medicine combined with an immunotherapeutic agent and application of the immunotherapeutic agent in preparation of the colorectal cancer medicine combined with the SIRT2 inhibitor. The research finds that the SIRT2 inhibitor AGK2 and the PD-1 antibody are used for jointly treating a colorectal cancer mouse, an obvious anti-tumor effect is achieved, and the lifetime of the colorectal cancer model mouse is prolonged. When the SIRT2 inhibitor is combined with the immunotherapeutic agent to treat colorectal cancer, a synergistic effect is achieved. The invention has a good clinical application prospect.

Tumor-selective expression of therapeutic molecules by bacteria is achieved by one or more AND, NOR, OR, NOT and / or NAND gate genetic circuits. The therapeutic molecules can be proteins, metabolites or catabolites, and may also be immunotherapeutics or immunotherapeutic cytotoxins. Single or multiple expression components may be used. Tumor selective expression of multimeric proteins utilizes multimerization as to complete the genetic circuit. Genetic circuits that are unlinked, function to achieve a combined effect on specificity of delivery of antitumor therapeutic molecules. Compositions and methods to generate silica, PEG and Poly-HPMA coated bacteria are also provided. Compositions and methods for selectively sensing or imaging tumors are also described.

This provides an improved method for treating malignant tumors in human patients. [Solution] A method comprising administering a therapeutically effective dose of a LAG-3 inhibitor; a PD-1 pathway inhibitor; and an immunotherapy agent.

The invention provides a linear or cyclic polypeptide and a derivative or analogue thereof, wherein the linear or cyclic polypeptide is used for mobilizing a stress-inducing protein (sestrin) from GATOR / mTOR to sMAC in a non-aging cell; the polypeptide comprises or consists of an amino acid sequence derived from a stress-inducing protein or a truncated sequence thereof. These polypeptides are useful in the treatment of conditions requiring immediate intervention, such as acute diseases, sepsis caused by pathogen infection, or anaphylaxis, such as allergic shock, as immunotherapeutic agents for the treatment of cancer, and for autoimmune diseases.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

The invention discloses a drug curative effect prediction model for probiotic combined treatment of colon cancer, a construction method and a device, and belongs to the technical field of biological medicines. The invention provides a method for treating colon cancer through combination of probiotics, a mathematical model is constructed at the same time, the influence of an alpha value on the speed of a system tending to be balanced is analyzed, and it is obtained that initial conditions only influence the speed of the system tending to be balanced and do not influence the stability of the system. Meanwhile, the analysis of the influence of the drug dosage on the immune system finds that the tumor removal time can be obviously shortened by the full-dose triple therapy, the curative effect is obviously improved compared with that of a single drug or double drugs, and the action mechanism of a combined therapy scheme is disclosed: the invasion and transfer rate of CD4 + T cells can be obviously improved by increasing probiotics while the chemical immunotherapy dosage is fixed; the anti-tumor mechanism of the probiotics is to accurately adjust the immune system.

Provided are methods and compositions for the treatment of cancer. The methods comprise administering to a subject an HDAC inhibitor and an immunotherapeutic agent. In certain instances the immunotherapeutic is an NK cell or a chimeric antigen receptor NK cell.

The application of poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers in constructing micro / nanocarriers for antitumor drugs belongs to the field of biomedical polymer materials and nanomedicine. The antitumor drugs are small-molecule chemotherapeutic agents, small-molecule photosensitizers, small-molecule immunotherapeutic agents, and small-molecule radiosensitizers. The particle size of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 10–5000 nm. The effective concentration of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers is 1–500 mg / kg. The antitumor mechanism of the poly(D-lactic acid) and poly(D-lactic acid-glycolic acid) copolymers includes increasing the activity of effector T cells in the tumor microenvironment and increasing the concentration of cytokines such as IFN-γ at the tumor site. In the field of tumor therapy, PLA and PLGA materials composed of D-lactic acid have shown good effects in inhibiting tumor growth, prolonging the survival period of tumor-bearing mice, and activating antitumor immune responses.

The present invention relates to the use of an anti-interleukin-6 agent prior to, simultaneously with, or after a CRS inducing immunotherapeutic agent.

Disclosed herein is the use of a copper chelating agent or an agent capable of inducing a copper chelating agent for the treatment of cancer, in particular for increasing the efficiency of an immunotherapy for the treatment of cancer. Disclosed herein are methods of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a copper chelating agent or a copper chelating agent inducer in combination with a therapeutically effective amount of an anti-cancer immunotherapeutic agent. Also disclosed herein are kits or combinations and compositions comprising a copper chelating agent or a copper chelating agent inducer and an anti-cancer immunotherapeutic agent, and uses thereof for the treatment of cancer.

The invention belongs to the field of tumor nano immunotherapy, and particularly relates to a nano immunotherapeutic agent cooperating with I / II type photodynamic and multiple cell death and anti-tumor application of the nano immunotherapeutic agent. The invention successfully constructs the nanoparticles (HMB) capable of targeting mitochondria and simultaneously exciting the photodynamic effects of the type I and the type II. Based on in-vitro and in-vivo experiments of a system, it is verified that ferroptosis and pyroptosis can be effectively triggered through photodynamic therapy mediated by the combination of the HMB and a ferroptosis inducer sulfasalazine. The multi-mode cell death network constructed by combining HMB with salazosulfapyridine represents a novel promising cancer treatment method, so that a novel strategy with transformation potential is provided for solid tumor treatment; and an important theoretical and practical basis is provided for deeply understanding a tumor cell death mechanism and designing a new-generation intelligent photosensitizer system according to the death mechanism.

The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.

The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and / or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.

Peptides, proteins, antibodies, antibody fragments, or antigen-binding fragments thereof, against cell adhesion molecules for use as immunotherapeutics.

Immunoglobulin complementarity determining regions (“CDRs”), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

The present invention relates to the use of an antibody or an immunologically active fragment thereof, which specifically binds to integrin β2, as an immuno-oncology agent. The chimeric and humanized antibodies of the present invention specifically bind to integrin β2, which is a tumor-specific antigen and is expressed on the cell membrane of M2 tumor-associated macrophages, and thus can be used as an antibody therapeutic agent for cancer treatment using a cancer cell death mechanism by immune cell activation, an antibody therapeutic agent for cancer treatment, or a cell therapeutic agent for cancer treatment, and can also be used for cancer diagnosis.

The present invention relates to cancer immunotherapy. In particular, the present invention provides methods, compounds, compositions and kits for treating and / or preventing cancer. Specifically, provided are methods for the treatment of cancer comprising administering a TLR2 agonist, such as a conjugate of dipalmitoyl-S-glyceryl-cysteine (Pam2Cys) and polyethylene glycol (PEG), more specifically a Pam2Cys-Ser-PEG compound, and an immunostimulatory agent, such as an anti-PD-1, anti-PDL-1, anti-PL-1, or anti-CTLA-4 immunotherapeutic agent.

A pharmaceutical combination product including:a liposomal formulation consisting of one or more liposomes each encapsulating a bacterial lipopolysaccharide (LPS) as a single active ingredient; andat least one anti-tumor compound chosen from the group consisting of: a therapeutic antibody, a chemotherapy agent, and an immunotherapy agent.Methods for treating a tumor comprising administering to a patient having said tumor an effective amount of said pharmaceutical combination product.

The present invention relates to carriers comprising mRNA encoding a HORMAD1 polypeptide, in particular mRNA-based vaccines, more in particular dendritic cell (DC) based vaccines. The present invention further relates to methods for preparing an immunotherapy agent and / or the use of the vaccines for inducing immune responses and preventing and / or treating subjects having cancer cells or tumors that express HORMAD1.

The present disclosure relates to a composition of a biologically pure isolate of the genus Salmonella comprising archival strain CRC1674, wherein the isolate further comprises a disruption of at least one gene selected from the group consisting of aroA, rfaH, and thyA and a chemotherapy agent, an immunotherapy agent, an androgen receptor antagonist, or a combination thereof. The present disclosure also relates to the method of use of this composition in treating cancer, particularly prostate cancer and pancreatic cancer.